"You’d think companies would want their products’ names to be memorable, catchy and descriptive: Windex, Duracell, KitchenAid ...

Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

Across the three-year clinical trial data for PsA and axSpA, BIMZELX was generally well-tolerated and no new safety signals were observed.2-4 The most common treatment-emergent adverse events ...

All patients received BIMZELX every four weeks (Q4W) to Week 16, then received either Q4W or Q8W depending upon response to treatment. Receiving Q4W to Week 16, then Q8W thereafter is the approved ...

Bimzelx is a type of medicine called a monoclonal antibody. Monoclonal antibodies are human-made antibodies created in the lab to mimic antibodies in the body. Bimzelx works by blocking two ...

These medicines act directly on the body’s immune system to help reduce symptoms. In 2023, Bimzelx was approved for the treatment of moderate or severe plaque psoriasis. Clinical studies show ...

UCB SA's solid buy case is driven by Bimzelx's impressive performance and robust financials despite a temporary 19% EBITDA decline due to product launch investments. Bimzelx, approved for ...

BIMZELX received FDA approval for PsA, nr-axSpA, and AS indications in September this year. The research presented at ACR demonstrates the long-term efficacy of BIMZELX, building on the breadth ...

BIMZELX ® is the first and only approved medicine designed to selectively inhibit interleukin 17A (IL-17A) in addition to interleukin 17F (IL-17F) ...

Sustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis (PSO) treated with ...